$3.92
-0.08 (-2.00%)
Open$4.03
Previous Close$4.00
Day High$4.43
Day Low$3.86
52W High$10.84
52W Low$3.02
Volume—
Avg Volume110.4K
Market Cap56.45M
P/E Ratio—
EPS$-3.49
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
+381.1% upside
Current
$3.92
$3.92
Target
$18.86
$18.86
$15.04
$18.86 avg
$28.67
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 292.3K | 388.6K | 28.89M |
| Net Income | -38,229,583 | -45,741,325 | 2.55M |
| Profit Margin | -13,086.5% | -12,432.2% | 8.8% |
| EBITDA | -31,532,062 | -39,823,795 | 4.88M |
| Free Cash Flow | — | — | 2.44M |
| Rev Growth | -24.8% | -24.8% | +0.1% |
| Debt/Equity | 1.99 | 1.99 | 0.72 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $295.03 | +0.20% | 50.3 | 520.47B |
| AMGN | Amgen Inc | $465.67 | -0.30% | 26.9 | 252.64B |
| GILD | Gilead Sciences Inc | $168.08 | +0.08% | — | 208.95B |
| VRTX | Vertex Pharmaceuticals Inc | $538.60 | -0.74% | 33.9 | 134.82B |
| REGN | Regeneron Pharmaceuticals | $955.47 | +0.45% | 20.4 | 98.38B |
| ALNY | Alnylam Pharmaceuticals Inc | $165.04 | +5.36% | 7.7 | 20.98B |